Atlas Trials

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

Clinical trial NCT04699461 · TERMINATED

Trial details

NCT number
NCT04699461
Sponsor
ADC Therapeutics S.A.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed Follicular LymphomaRefractory Follicular Lymphoma
Start date
2021-11-04
Primary completion
2022-11-25
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.